Studybox Research CLIA Waiver Studies
H. pylori Stool Antigen Test
Accuracy in the hands of untrained intended-use operators at waived sites.
Studybox
CLIA Waiver Studies
Stool antigen testing detects active H. pylori infection, unlike serology, which remains positive after eradication, and the clinical study is built around that distinction. Subjects are classified as infected or not by biopsy-based methods at endoscopy or by urea breath test, and recent use of proton pump inhibitors, bismuth or antibiotics suppresses bacterial load and lowers stool antigen sensitivity, so a washout period is a standard eligibility criterion that removes a meaningful share of candidates.
A test-of-eradication claim adds a second visit several weeks after completion of therapy, which is unusual in IVD studies and introduces retention risk. Enrollment typically centers on gastroenterology and endoscopy practices with the reference method on hand, while waived-setting data for the device itself come from primary care and urgent care staff running the test on stool returned by patients.
- Analyte
- Helicobacter pylori antigen in stool
- Therapeutic area
- Gastrointestinal Health
- Specimens
- Stool
- Intended-use settings
- physician office, urgent care, hospital POC
- Operators
- Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.
- Comparator
- Typically a composite reference of biopsy-based methods (histology and rapid urease test, with or without culture) obtained at endoscopy, or urea breath test where endoscopy is not performed; the protocol defines how a subject is classified as infected.
CLIA Waiver Studies specifics
What Changes for This Assay on This Pathway.
- Stool handling by untrained operators (sampling the correct amount from a returned container, suspending in buffer, drop count) is the operator-dependent step; flex studies typically stress sample amount, buffer mixing, read time and specimen storage temperature before testing.
- Waived sites receive patient-collected stool that may have been held for a variable time; the waiver study should reflect realistic return intervals within the labeled stability.
- Primary care and urgent care sites supply the operators, but subjects with an endoscopic reference typically come from gastroenterology practices; the two-site structure must preserve untrained operator status at the testing site.
Endpoints the study must support
- Sensitivity and specificity against the composite reference for active infection, with 95% confidence intervals
- For a test-of-eradication claim, performance at a defined interval after completion of therapy against the same reference
- Invalid rate and inter-operator agreement for visually read devices in waived settings
Enrollment realities
Driven by infected subjects with an adequate reference, which depends on access to endoscopy or breath testing; medication washout exclusions and stool return compliance are predictable losses. U.S. prevalence is modest, so site selection targets referral populations.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run clia waiver studies →
Same assay, other pathways
Relevant FDA guidance
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
FAQ
H. pylori Stool Antigen Test Study Questions.
01 Who operates the h. pylori stool antigen test in a clia waiver studies study?
Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.
02 What is the comparator for a h. pylori stool antigen test study?
Typically a composite reference of biopsy-based methods (histology and rapid urease test, with or without culture) obtained at endoscopy, or urea breath test where endoscopy is not performed; the protocol defines how a subject is classified as infected.
03 What drives enrollment for a h. pylori stool antigen test study?
Driven by infected subjects with an adequate reference, which depends on access to endoscopy or breath testing; medication washout exclusions and stool return compliance are predictable losses. U.S. prevalence is modest, so site selection targets referral populations.
Let's talk IVD research
Planning a h. pylori stool antigen test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the clia waiver studies pathway.